JLR Commentaries

Subscribe to collection
FilterHide Filter
  • Commentary
    Open Access

    HDL, heart disease, and the lung

    Journal of Lipid Research
    Vol. 63Issue 6100217Published online: April 26, 2022
    • Kathrin Frey
    • Arnold von Eckardstein
    Cited in Scopus: 0
      For more than 50 years, a low plasma level of HDL-cholesterol has been known as an independent risk factor of atherosclerotic cardiovascular diseases (ASCVD). In addition, HDL particles exert a plethora of potentially anti-atherogenic activities on many cells including endothelial cells, smooth muscle cells, as well as monocyte-derived macrophages and other inflammatory cells. Nevertheless, therapeutic interventions raising HDL-cholesterol did not improve the prevention of cardiovascular events beyond standard therapy with statins.

    ASBMB  ASBMB  ASBMB  ASBMB

    ISSN 0022-2275
    We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
    Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


    RELX